556 related articles for article (PubMed ID: 21859995)
21. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Colangelo LH; Lopa SH; Petrelli NJ; Goldberg RM; Atkins JN; Seay TE; Fehrenbacher L; O'Reilly S; Chu L; Azar CA; Wolmark N
J Clin Oncol; 2009 Jul; 27(20):3385-90. PubMed ID: 19414665
[TBL] [Abstract][Full Text] [Related]
22. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
Twelves C
Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
[No Abstract] [Full Text] [Related]
23. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
[TBL] [Abstract][Full Text] [Related]
24. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Kuebler JP; Colangelo L; O'Connell MJ; Smith RE; Yothers G; Begovic M; Robinson B; Seay TE; Wolmark N
Cancer; 2007 Nov; 110(9):1945-50. PubMed ID: 17853393
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
26. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
28. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Wolmark N; Colangelo L; Wieand S
Semin Oncol; 2001 Feb; 28(1 Suppl 1):9-13. PubMed ID: 11273592
[TBL] [Abstract][Full Text] [Related]
29. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
[TBL] [Abstract][Full Text] [Related]
30. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Andre T; Colin P; Louvet C; Gamelin E; Bouche O; Achille E; Colbert N; Boaziz C; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Buyse M; de Gramont A
J Clin Oncol; 2003 Aug; 21(15):2896-903. PubMed ID: 12885807
[TBL] [Abstract][Full Text] [Related]
31. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
Sharif S; O'Connell MJ; Yothers G; Lopa S; Wolmark N
Cancer Invest; 2008 Nov; 26(9):956-63. PubMed ID: 18798075
[TBL] [Abstract][Full Text] [Related]
32. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Alberts SR; Sargent DJ; Nair S; Mahoney MR; Mooney M; Thibodeau SN; Smyrk TC; Sinicrope FA; Chan E; Gill S; Kahlenberg MS; Shields AF; Quesenberry JT; Webb TA; Farr GH; Pockaj BA; Grothey A; Goldberg RM
JAMA; 2012 Apr; 307(13):1383-93. PubMed ID: 22474202
[TBL] [Abstract][Full Text] [Related]
33. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
35. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
36. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L; Wang Y; Cai C; Ding Y; Kim RS; Lipchik C; Gavin PG; Yothers G; Allegra CJ; Petrelli NJ; Suga JM; Hopkins JO; Saito NG; Evans T; Jujjavarapu S; Wolmark N; Lucas PC; Paik S; Sun M; Pogue-Geile KL; Lu X
J Clin Oncol; 2024 May; 42(13):1520-1530. PubMed ID: 38315963
[TBL] [Abstract][Full Text] [Related]
37. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
38. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Petrelli NJ; Lopa SH; Wolmark N
J Clin Oncol; 2013 Jan; 31(3):359-64. PubMed ID: 23233715
[TBL] [Abstract][Full Text] [Related]
40. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
